Cayuga Medical Center Internal Medicine

Topics

• Chronic Lymphocytic Leukemia Research 123
• Lymphoma Diagnosis and Treatment 22
• CAR-T cell therapy research 9
• SARS-CoV-2 and COVID-19 Research 5
• Sepsis Diagnosis and Treatment 5
• Methemoglobinemia and Tumor Lysis Syndrome 4
• Atrial Fibrillation Management and Outcomes 3
• Cutaneous lymphoproliferative disorders research 3
• Diversity and Career in Medicine 3
• Hematopoietic Stem Cell Transplantation 3
• Multiple Myeloma Research and Treatments 3
• Acute Lymphoblastic Leukemia research 2

Most cited

1. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 573 citations · Anthony Mato

2. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

   Lancet (London, England) · 2021 · 391 citations · Anthony Mato

3. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

   The New England journal of medicine · 2023 · 204 citations · Anthony Mato

4. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.

   Science (New York, N.Y.) · 2024 · 133 citations · Anthony Mato

5. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

   Blood · 2022 · 216 citations · Anthony Mato

6. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

   The New England journal of medicine · 2022 · 232 citations · Anthony Mato